Domo signs strategic collaboration agreement with AWS for AI solutions
SANTA MONICA, Calif. - GoodRx Holdings, Inc. (NASDAQ:GDRX) saw its shares jump 6% after the prescription savings platform provider issued stronger-than-expected guidance for the first quarter, overshadowing a slight miss on fourth-quarter results.
The company reported fourth-quarter adjusted earnings per share of $0.09, falling short of analysts’ estimates of $0.10. Revenue for the quarter came in at $198.6 million, just below the consensus estimate of $199.76 million. However, revenue increased 0.4% compared to the same quarter last year.
Despite the miss, GoodRx provided an optimistic outlook for the first quarter of 2025, projecting revenue between $201 million and $205 million, above the analyst consensus of $202.6 million. The company also expects an adjusted EBITDA margin of approximately 33% for Q1, up from 31.7% in the same period last year.
For the full year 2024, GoodRx reported revenue of $792.3 million, a 6% increase YoY. The company’s net income for the year was $16.4 million, compared to a net loss of $8.9 million in 2023.
"I am excited to join GoodRx at such a pivotal time for both the company and healthcare system as a whole," said Wendy Barnes, Chief Executive Officer and President of GoodRx. "I’m thrilled to be here and am optimistic about the endless opportunities we have."
The company ended the fourth quarter with over 7 million consumers using its prescription-related offerings, highlighting its growing user base.
GoodRx’s focus on capital allocation and strategic priorities, including investing for profitable growth and paying down debt, appears to have resonated with investors, as reflected in the positive stock movement following the earnings release.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.